Q2 2018 13F Holders as of 30 Jun 2018
-
Type / Class
-
Equity / Ordinary Shares, nominal value 0.05 GBP per share
-
Shares outstanding
-
84,213,667
-
Number of holders
-
13
-
Total 13F shares, excl. options
-
6,490,956
-
Shares change
-
-91,179
-
Total reported value, excl. options
-
$71,091,000
-
Value change
-
-$1,254,345
-
Number of buys
-
2
-
Number of sells
-
-5
-
Price
-
$13.66
Significant Holders of Verona Pharma plc - Ordinary Shares, nominal value 0.05 GBP per share (VRNA) as of Q2 2018
15 filings reported holding VRNA - Verona Pharma plc - Ordinary Shares, nominal value 0.05 GBP per share as of Q2 2018.
Verona Pharma plc - Ordinary Shares, nominal value 0.05 GBP per share (VRNA) has 13 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 6,490,956 shares
of 84,213,667 outstanding shares and own 7.71% of the company stock.
Largest 10 shareholders include Vivo Capital, LLC (1,492,951 shares), ORBIMED ADVISORS LLC (1,250,396 shares), NEA Management Company, LLC (1,219,674 shares), venBio Partners L.P. (875,000 shares), Novo Holdings A/S (740,740 shares), Foresite Capital Management III, LLC (502,825 shares), Tekla Capital Management LLC (275,000 shares), Polar Capital LLP (100,000 shares), PERCEPTIVE ADVISORS LLC (22,327 shares), and DEUTSCHE BANK AG\ (6,467 shares).
This table shows the top 13 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.